Two companies have been approved by the FDA to begin working on drugs that are based on this. There's a lot of basic work to be done in terms of pharmacology and neuroscience, trying to understand the underlying mechanisms for both acute effects and enduring effects. But I would have some optimism that those initial indications which are targeted at either treatment, resistant depression or major depression are likely approval indications. And then there are a variety of other indications.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode